AU2017260323B2 - Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same - Google Patents

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Download PDF

Info

Publication number
AU2017260323B2
AU2017260323B2 AU2017260323A AU2017260323A AU2017260323B2 AU 2017260323 B2 AU2017260323 B2 AU 2017260323B2 AU 2017260323 A AU2017260323 A AU 2017260323A AU 2017260323 A AU2017260323 A AU 2017260323A AU 2017260323 B2 AU2017260323 B2 AU 2017260323B2
Authority
AU
Australia
Prior art keywords
lys
glu
asp
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017260323A
Other languages
English (en)
Other versions
AU2017260323A1 (en
Inventor
Luc Berghman
Lisa Bielke
Leona Nicole Calhoun
Olivia B. Faulkner
Billy Hargis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
University of Arkansas at Little Rock
Original Assignee
Texas A&M University System
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, University of Arkansas at Fayetteville, University of Arkansas at Little Rock filed Critical Texas A&M University System
Publication of AU2017260323A1 publication Critical patent/AU2017260323A1/en
Priority to AU2023255055A priority Critical patent/AU2023255055A1/en
Application granted granted Critical
Publication of AU2017260323B2 publication Critical patent/AU2017260323B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
AU2017260323A 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Ceased AU2017260323B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023255055A AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331044P 2016-05-03 2016-05-03
US62/331,044 2016-05-03
PCT/US2017/030764 WO2017192671A1 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023255055A Division AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Publications (2)

Publication Number Publication Date
AU2017260323A1 AU2017260323A1 (en) 2018-12-20
AU2017260323B2 true AU2017260323B2 (en) 2023-11-16

Family

ID=60203263

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017260323A Ceased AU2017260323B2 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU2023255055A Abandoned AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023255055A Abandoned AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Country Status (12)

Country Link
US (2) US10682398B2 (https=)
EP (1) EP3452069A4 (https=)
JP (3) JP7467027B2 (https=)
KR (2) KR20190015712A (https=)
AR (1) AR108688A1 (https=)
AU (2) AU2017260323B2 (https=)
BR (1) BR112018072592A2 (https=)
CA (1) CA3023144A1 (https=)
MX (1) MX2018013331A (https=)
SG (1) SG11201809686SA (https=)
TW (2) TWI843057B (https=)
WO (1) WO2017192671A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
EP3996731A4 (en) * 2019-07-12 2023-07-12 Op-T Llc PEPTIDES AND METHODS OF TREATMENT OF DISEASES
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
JP2025127116A (ja) 2024-02-20 2025-09-01 セイコーエプソン株式会社 液体吐出装置及び液体吐出装置の制御方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (en) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0574466T3 (da) 1991-03-05 1999-11-08 Wellcome Found Udtrykkelse af rekombinante proteiner i svækkede bakterier
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
ATE173166T1 (de) 1992-09-04 1998-11-15 Univ Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DK0812206T3 (da) 1995-03-01 2002-09-09 Immunex Corp Fremgangsmåde til stimulering af en immunrespons
MX9709447A (es) 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
CA2313805A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
PT1108034E (pt) 1998-09-04 2008-11-14 Emergent Product Dev Uk Ltd Mutantes de spi2 de salmonela atenuados como transportadores de antigénios
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
WO2000063395A1 (en) 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
TR200401569T4 (tr) 1999-12-28 2004-07-21 Akzo Nobel N.V. Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
ATE412427T1 (de) 2000-02-02 2008-11-15 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1392844A4 (en) 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
JP2005511770A (ja) 2001-12-19 2005-04-28 アルケド バイオテック ゲーエムベーハー Ｈｍｇｂタンパク質およびｈｍｇｂタンパク質をコードする核酸の使用方法
MXPA04005909A (es) 2001-12-21 2005-05-17 Immunex Corp Polipeptidos recombinantes.
AU2003215254A1 (en) 2002-02-13 2003-09-04 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ATE556596T1 (de) 2002-04-15 2012-05-15 Univ St Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
JP2006506441A (ja) 2002-11-20 2006-02-23 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
CA2506328A1 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
JP2008501625A (ja) 2003-11-21 2008-01-24 エース バイオサイエンシズ エー／エス 表在Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉポリペプチド
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006083301A2 (en) 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
AU2005321630A1 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
ATE489455T1 (de) 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
CN101330928B (zh) 2005-10-07 2012-11-14 西马生物医学计划公司 用于预防和治疗丙型肝炎的免疫刺激剂组合
CA2628837C (en) 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
WO2007130520A2 (en) * 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
EP2056872A4 (en) 2006-08-09 2016-12-21 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
BRPI0718273A2 (pt) * 2006-10-27 2013-11-12 Dow Agrosciences Llc Vacina para aves domésticas, para enterite necrótica, compreendendo um antígeno de toxina clostridium perfringens mutante, e métodos de produção da vacina
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
WO2009009215A2 (en) 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
JP2011502165A (ja) 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
DK2329266T3 (en) 2008-09-11 2016-07-18 Pasteur Institut MONITORING AND INHIBITING INFECTION WITH HUMAN IMMUNE DEFECT VIRUS BY MODULATING HMGB1-DEPENDENT TRACTOR OF HIV-1 REPLICATION AND PERSISTENCE
US8163281B2 (en) 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
DK2365332T3 (da) 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
NZ708065A (en) 2012-10-29 2019-07-26 Univ Arkansas Novel mucosal adjuvants and delivery systems
CA2906079C (en) * 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2015269415A1 (en) 2014-06-05 2017-01-05 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (en) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Also Published As

Publication number Publication date
US20170319671A1 (en) 2017-11-09
SG11201809686SA (en) 2018-11-29
AR108688A1 (es) 2018-09-19
JP2024023648A (ja) 2024-02-21
WO2017192671A1 (en) 2017-11-09
JP2022040389A (ja) 2022-03-10
CA3023144A1 (en) 2017-11-09
US10682398B2 (en) 2020-06-16
KR102767638B1 (ko) 2025-02-20
MX2018013331A (es) 2019-06-10
KR20190015712A (ko) 2019-02-14
US20200297825A1 (en) 2020-09-24
JP7467027B2 (ja) 2024-04-15
KR20230070521A (ko) 2023-05-23
TW201803590A (zh) 2018-02-01
EP3452069A4 (en) 2020-02-12
BR112018072592A2 (pt) 2019-04-16
AU2017260323A1 (en) 2018-12-20
AU2023255055A1 (en) 2023-11-16
JP2019514971A (ja) 2019-06-06
TWI758288B (zh) 2022-03-21
EP3452069A1 (en) 2019-03-13
US11382962B2 (en) 2022-07-12
TW202224701A (zh) 2022-07-01
TWI843057B (zh) 2024-05-21

Similar Documents

Publication Publication Date Title
AU2017260323B2 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU2017205270B2 (en) Therapeutic anticancer neoepitope vaccine
AU2017300965B2 (en) Biofusion proteins as anti-malaria vaccines
AU2020218330B2 (en) Probiotic compositions comprising lactobacillus reuteri strains and methods of use
AU2019336031B2 (en) Chimeric antigen receptor for solid cancer and T cells expressing chimeric antigen receptor
AU2020332969B2 (en) Anti-PD-L1 single domain antibodies
AU2020411873B2 (en) Mutant RSV F protein and use thereof
AU2020366472B2 (en) Carrier protein with site-directed mutation and use thereof in preparation of vaccine
DK2214701T3 (en) CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
AU2022336191A1 (en) Helicobacter pylori composite antigen, antibody, preparation method and use
AU2022207569A9 (en) Stable preparation of human papillomavirus virus-like particle vaccine
CA2273199A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU2017235361B2 (en) Means and methods for treating HSV
CA2135200C (en) Canine coronavirus s gene and uses therefor
EP0696322A1 (en) METHODS AND COMPOSITIONS FOR $i(SALMONELLA)-BASED VACCINES
CA2278116A1 (en) Abundant extracellular products and methods for their production and use
CA2435151A1 (en) Method for treating psoriasis
CN103917244B (zh) 用于提高细胞表面的etec cs6抗原呈递的方法及可由其获得的产物
US11497801B2 (en) Compositions and methods of enhancing immune responses
EP4370150A1 (en) Overcoming antibody-interference in avians
CA2365451A1 (en) Nucleic acid molecule comprising a nucleic acid sequence coding for a hemocyanin
CA2385822A1 (en) Essential gene and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
WO2021178891A1 (en) Live salmonella typhi vectors engineered to express protein antigens and methods of use thereof
CA2400876A1 (en) Novel protein and gene encoding the protein

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired